Drug Delivery Methods Research Articles

Current trends and prospects of the local antihypertensive drugs development for the glaucoma treatment

Glaucoma is one of the world’s primary causes of blindness. Russia is following the global increasing trends of glaucoma and its leading position among ophthalmic pathologies that cause irreversible loss of vision. Elevated intraocular pressure (IOP) is the only modifiable risk factor of glaucoma, so treatment strategies specifically focus on reducing IOP by suppressing the production of intraocular fluid and boosting its outflow. The current review presents new medications aimed at glaucoma and high IOP control that have recently appeared at the international market as well as the drugs under the different stages of development, from experimental to clinical studies. These include both the developments of agents belonging to the existing classes and of entirely new drugs intended to control IOP. In an attempt to reduce the side effects of locally administered drugs and prolong their action, in parallel with the development of new drugs, there is also evidence of alternative methods of drug delivery: intraocular implants, injectable forms and obturators, combinations of polymers and colloidal systems.

Navigating the Alzheimer's Treatment Landscape: Unraveling Amyloid-Beta Complexities and Pioneering Precision Medicine Approaches.

A variety of cutting-edge methods and good knowledge of the illness's complex causes are causing a sea change in the field of Alzheimer's Disease (A.D.) research and treatment. Precision medicine is at the vanguard of this change, where individualized treatment plans based on genetic and biomarker profiles give a ray of hope for customized therapeutics. Combination therapies are becoming increasingly popular as a way to address the multifaceted pathology of Alzheimer's by simultaneously attacking Aβ plaques, tau tangles, neuroinflammation, and other factors. The article covers several therapeutic design efforts, including BACE inhibitors, gamma- secretase modulators, monoclonal antibodies (e.g., Aducanumab and Lecanemab), and anti- Aβ vaccinations. While these techniques appear promising, clinical development faces safety concerns and uneven efficacy. To address the complicated Aβ pathology in Alzheimer's disease, a multimodal approach is necessary. The statement emphasizes the continued importance of clinical trials in addressing safety and efficacy concerns. Looking ahead, it suggests that future treatments may take into account genetic and biomarker traits in order to provide more personalized care. Therapies targeting Aβ, tau tangles, neuroinflammation, and novel drug delivery modalities are planned. Nanoparticles and gene therapies are only two examples of novel drug delivery methods that have the potential to deliver treatments more effectively, with fewer side effects, and with better therapeutic results. In addition, medicines that target tau proteins in addition to Aβ are in the works. Early intervention, based on precise biomarkers, is a linchpin of Alzheimer's care, emphasizing the critical need for detecting the disease at its earliest stages. Lifestyle interventions, encompassing diet, exercise, cognitive training, and social engagement, are emerging as key components in the fight against cognitive decline. Data analytics and art are gaining prominence as strategies to mitigate the brain's inflammatory responses. To pool knowledge and resources in the fight against Alzheimer's, international cooperation between scientists, doctors, and pharmaceutical companies is still essential. In essence, a complex, individualized, and collaborative strategy will characterize Alzheimer's research and therapy in the future. Despite obstacles, these encouraging possibilities show the ongoing commitment of the scientific and medical communities to combat A.D. head-on, providing a glimmer of hope to the countless people and families touched by this savage sickness.

Coaxial nanofibrous aerogel featuring porous network-structured channels for ovarian cancer treatment by sustained release of chitosan oligosaccharide

Ovarian cancer, the deadliest gynecological malignancy, primarily treated with chemotherapy. However, systemic chemotherapy often leads to severe toxic side effects and chemoresistance. Drug-loaded aerogels have emerged as a promising method for drug delivery, as they can improve drug solubility and bioavailability, control drug release, and reduce drug distribution in non-targeted tissues, thereby minimizing side effects. In this research, chitosan oligosaccharide (COS)-loaded nanofibers composite chitosan (CS) aerogels (COS-NFs/CS) with a porous network structure were created using nanofiber recombination and freeze-drying techniques. The core layer of the aerogel has a COS loading rate of 60 %, enabling the COS-NFs/CS aerogel to significantly inhibit the migration and proliferation of ovarian cancer cells (resulting in a decrease in the survival rate of ovarian cancer cells to 33.70 % after 48 h). The coaxial fiber's unique shell-core structure and the aerogel's porous network structure enable the COS-NFs/CS aerogels to release COS steadily and slowly over 30 days, effectively reducing the initial burst release of COS. Additionally, the COS-NFs/CS aerogels exhibit good biocompatibility, degradability (only retaining 18.52 % of their weight after 6 weeks of implantation), and promote angiogenesis, thus promoting wound healing post-oophorectomy. In conclusion, COS-NFs/CS aerogels show great potential for application in the treatment of ovarian cancer.

Advance and opportunities in nanoparticle drug delivery for central nervous system disorders: A review of current advances

Nanoparticles drug delivery systems have emerged as a cutting-edge approach in treating central nervous system disorders. This review discusses the advancements and opportunities in utilizing nanoparticles for targeted drug delivery to the brain, focusing on their potential to enhance efficacy, reduce side effects, and improve patient outcomes. Lipid-based nanocarriers like liposomes, solid lipid nanoparticles (SLNs) and micelles are widely used in neurological conditions. The growing demand for innovative drug delivery methods for treating neurodegenerative disorders, such as Parkinson's and Alzheimer’s are largely due to potential therapy failures in the blood brain barrier and P-glycoproteins which cause progressive loss of brain function. Nanotechnology advancements can help overcome these limitations by improving the delivery of active medicine campaigns and creating nanomaterials that improve active drug delivery.

Preparation and Characterization of Sustained Release Risperidone Loaded Eudragit Microparticles by Spray-Drying Technique

The goal of this work was to create novel risperidone-containing spray-dried microparticles using Eudragit® L100, a methacrylic polymer. Microparticles were designed with controlled release and enhanced in-vitro effects in mind and were meant to be taken orally. Spray-drying was used to create Eudragit® L100 microparticles loaded with risperidone. Risperidone-loaded Eudragit® L100 was successfully prepared to treat mental/mood disorders, according to an investigation into its physicochemical properties in-vitro. Spray-drying was an effective method for producing Eudragit® L100 microparticles loaded with risperidone. Formulations displayed a suitable drug entrapment percentage or nearly 89.94%. The mean diameter of the nearly spherical and spherical microparticles ranged from 30 to 50 μm, and they had a smooth surface. The distinctive peak of risperidone loaded with Eudragit L100 was visible in the fourier-transformed infrared (FTIR) spectra, indicating that the medication was fully encapsulated in the polymer. The dissolution rate of risperidone-loaded microparticles was slower than that of the pure medication. The use of spray-dried risperidone microparticles as a practical oral drug delivery method for more effective and regulated risperidone release is supported experimentally by our results.

Innovative Nanotechnology in Drug Delivery Systems for Advanced Treatment of Posterior Segment Ocular Diseases.

Funduscopic diseases, including diabetic retinopathy (DR) and age-related macular degeneration (AMD), significantly impact global visual health, leading to impaired vision and irreversible blindness. Delivering drugs to the posterior segment of the eye remains a challenge due to the presence of multiple physiological and anatomical barriers. Conventional drug delivery methods often prove ineffective and may cause side effects. Nanomaterials, characterized by their small size, large surface area, tunable properties, and biocompatibility, enhance the permeability, stability, and targeting of drugs. Ocular nanomaterials encompass a wide range, including lipid nanomaterials, polymer nanomaterials, metal nanomaterials, carbon nanomaterials, quantum dot nanomaterials, and so on. These innovative materials, often combined with hydrogels and exosomes, are engineered to address multiple mechanisms, including macrophage polarization, reactive oxygen species (ROS) scavenging, and anti-vascular endothelial growth factor (VEGF). Compared to conventional modalities, nanomedicines achieve regulated and sustained delivery, reduced administration frequency, prolonged drug action, and minimized side effects. This study delves into the obstacles encountered in drug delivery to the posterior segment and highlights the progress facilitated by nanomedicine. Prospectively, these findings pave the way for next-generation ocular drug delivery systems and deeper clinical research, aiming to refine treatments, alleviate the burden on patients, and ultimately improve visual health globally.

Non-surgical Synergistic Interventions for the Treatment of Skin Cancer.

Skin cancer is broadly classified into two categories i.e., non-melanoma skin cancer (NMSC) and malignant melanoma (MM), with MM having a greater fatality rate than NMSC. A large number of treatment strategies currently exist for these skin cancer types, ranging from monotherapies to complex multifaceted synergistic interventions including dual therapies, trimodality therapy, and multicomponent combinations therapy. These combinatorial cancer treatments have delivered more favorable results when compared with monotherapies, and although combination treatments increase the cost of treatment, these regimens have lower side effect profiles, decreased resistance, high efficacy and an improved long-term response. Synergistic combination treatments for skin cancer are often complex, wide-ranging and encompass diverse platforms with various mechanisms of action. An understanding of the physiological potential, as well the efficacy of such treatments, is therefore vital to ensure patients receive the best possible treatment. This review therefore focuses on the current advancements and existing non-surgical combinative drug delivery methods utilized for treating skin cancer. It encompasses the diverse pharmaceutical delivery systems, clinical outcomes, and oncology strategies employed and aims to highlight the role of non-surgical combination therapies in enhancing patient compliance, reducing treatment durations, and improving overall survival rates while addressing relapses and metastasis. The promising outlook of the research being conducted in this field has also been provided, as well as the barriers to the effective treatment of this complex condition.

An Insight into Cubosomal Drug Delivery Approaches: An Explicative Review.

Cubosomes, a novel drug delivery system, have gained significant attention in recent years due to their unique self-assembled structures and enhanced drug encapsulation capabilities. They are administered by oral, ophthalmic, transdermal, and chemotherapeutic routes, to name a few. Due to their many potential benefits-which include high drug dispersal due to the cubic structure, a large surface area, a relatively simple manufacturing process, biodegradability, the capacity to encapsulate hydrophobic, hydrophilic, and amphiphilic compounds, targeted and controlled release of bioactive agents, and the biodegradability of lipids-cubosomes show enormous promise in drug nanoformulations for cancer therapeutics. The most common preparation method involves emulsifying a monoglyceride with a polymer, homogenizing, and then sonicating the mixture. Two distinct approaches to preparing are top-down and bottom-up. This evaluation will examine the materials, methods of preparation, cubosome-related drug encapsulating techniques, drug loading, release mechanism, and their uses. The following databases were used for literature searches: PubMed, Frontiers, Science Direct, Springer, Wiley, and MDPI. For the purpose of finding pertinent articles and contents (2015-2024), the keywords "cubosome; drug delivery systems, nano-carrier, theranostic, drug release mechanism" and others of a similar nature were utilized. This review will conduct a comprehensive analysis of the cubosome-related composition, production methods, drug encapsulating strategies, drug release mechanisms, and applications. Moreover, the difficulties encountered in fine-tuning different parameters to improve loading capabilities and prospects are also discussed. Innovation in pharmaceutical research and development can be stimulated by the knowledge gathered about cubosomal drug delivery methods. Through the clarification of the mechanisms involved in drug release from cubosomes and the investigation of innovative fabrication procedures, scientists can enhance the cubosomal formulation design for targeted therapeutic uses. </p>.

A novel pH-sensitive drug carrier system based on 18-crown ether-6/sodium alginate for curcumin/nido-carborane encapsulation: Studies of release properties, cell imaging and bioactivity evaluation

Curcumin's remarkable anti-tumor action has drawn a lot of interest, however its low bioavailability, poor targeting, and poor water solubility restrict its therapeutic potential. Two fluorescent polymers based on curcumin/nido-carborane-crown ether were produced using a two-phase technique in this study: Cur/Carborane-C/SA (encapsulated with sodium alginate) and Cur/Carborane-C (without sodium alginate). Cur/Carborane-C/SA was thought to be the most promising polymer with anti-tumor properties. The drug delivery method based on the polymer created by tris (3-aminoethyl) amine (TAEA) and 18-crown ether-6 in combination with sodium alginate offers a novel approach to curcumin encapsulation technology. Nido-carborane improves the targeting of curcumin and its tumor-cell-inhibiting properties. Good fluorescence qualities were shown by Cur/Carborane-C/SA's fluorescence quantum yield of 0.119 %. According to in vitro drug release data, the polymer performed well for pH response release at 5.0. The TEM and particle size data demonstrated that curcumin produced uniformLy sized, difficult to agglomerate nanoparticles with a particle size of less than 300 nm. The polymer exhibited a substantial affinity and inhibition of HCT-116 and HeLa cells, with an inhibition rate that may reach 78.3 %, according to the findings of the cytotoxicity assay and cell imaging. As a result, it is anticipated that the produced Cur/Carborane-C/SA would provide a new pH-responsive drug carrier system for curcumin intended for use in cancer treatment.

Physico-Chemical Study of the Anti-Diabetic Drug of [BzN-EJJ-amide] for Treatment Type2 Diabetes Using CNT Sensor by Drug Delivery Method

Physico-Chemical Study of the Anti-Diabetic Drug of [BzN-EJJ-amide] for Treatment Type2 Diabetes Using CNT Sensor by Drug Delivery Method

Rose Bengal Labeled Bovine Serum Albumin for Protein Transport Imaging in Subcutaneous Tissues Using Computed Tomography and Fluorescence Microscopy.

Subcutaneous (SC) injection of protein-based therapeutics is a convenient and clinically established drug delivery method. However, progress is needed to increase the bioavailability. Transport of low molecular weight (Mw) biotherapeutics such as insulin and small molecule contrast agents such as lipiodol has been studied using X-ray computed tomography (CT). This analysis, however, does not translate to the investigation of higher Mw therapeutics, such as monoclonal antibodies (mAbs), due to differences in molecular and formulation properties. In this study, an iodinated fluorescein analog rose bengal (RB) was used as a radiopaque and fluorescent label to track the distribution of bovine serum albumin (BSA) compared against unconjugated RB and sodium iodide (NaI) via CT and confocal microscopy following injection into ex vivo porcine SC tissue. Importantly, the high concentration BSA-RB exhibited viscosities more like that of viscous biologics than the small molecule contrast agents, suggesting that the labeled protein may serve as a more suitable formulation for the investigation of injection plumes. Three-dimensional (3D) renderings of the injection plumes showed that the BSA-RB distribution was markedly different from unconjugated RB and NaI, indicating the need for direct visualization of large protein therapeutics using conjugated tags rather than using small molecule tracers. Whereas this proof-of-concept study shows the novel use of RB as a label for tracking BSA distribution, our experimental approach may be applied to high Mw biologics, including mAbs. These studies could provide crucial information about diffusion in SC tissue and the influence of injection parameters on distribution, transport, and downstream bioavailability.

Emerging Technologies in Endocrine Drug Delivery: Innovations for Improved Patient Care.

Recent advancements in drug delivery systems for endocrine disorders have significantly improved patient outcomes by addressing the limitations of traditional methods such as oral tablets and injections. These innovations include non-invasive alternatives like inhaled insulin, which provides rapid absorption and better patient compliance, and robotic pills that deliver drugs directly to specific gastrointestinal sites, enhancing absorption and reducing side effects. Wearable artificial pancreas systems have revolutionized diabetes management by integrating continuous glucose monitoring with insulin pumps to automate blood glucose control. These systems demonstrate superior glycemic control and reduce hypoglycemic events. Additionally, smart insulin pens enhance diabetes care through dose tracking and real-time data sharing, improving accuracy and adherence. Microneedle patches offer a minimally invasive method for transdermal drug delivery, effectively administering hormones and therapeutic peptides without the pain and inconvenience of injections. These patches dissolve after use, eliminating biohazardous waste. Implantable devices provide long-term, controlled release of medications, significantly improving adherence and glycemic control of patients with diabetes. Hydrogels also offer new drug delivery options. This review examines these technologies' clinical efficacy, safety, advantages, and limitations, highlighting their potential to transform endocrine disorder management. Integrating advanced delivery systems marks a significant step towards personalized medicine, tailoring treatments to individual patient needs for better health outcomes.

Unveiling the Potential of Surface Active Ionic Liquids Based Catanionic Vesicles for Tailored Delivery of Curcumin and its Enhanced Therapeutic Efficacy

AbstractNano vehicles for drug delivery with stimuli‐responsive characteristics are gaining prominence due to their ability to enhance traditional drug delivery methods by minimizing side effects and improving drug efficacy. Among the various stimuli‐responsive systems, pH‐responsive drug delivery nano vehicles have garnered significant attention. Utilizing this pH variance, tailored drug delivery nano vehicles can release encapsulated drugs on demand. Here, we developed pH‐responsive catanionic vesicles to create customized drug delivery nano vehicles responsive to stimuli, particularly pH. we have designed catanionic vesicles through interacting two oppositely charged surface active ionic liquids (SAILs), i. e. cationic ‐methyl‐4‐(2‐(dodecyloxycarbonylmethyl)morpholin‐4‐ium bromide [C12EMorph][Br] with anionic Choline Oleate ([Ch][Ol]). The spherically shaped micellar aggregates of [C12EMorph][Br] are transformed into pH responsive vesicular nanoaggregates through judicious addition of [Ch][Ol]. The morphological transition was studied through various analytical techniques including DLS, FRET and SANS. We used these pH responsive vesicular nanoaggregates to load representative hydrophobic drug curcumin in order to enhance its solubility, efficacy and bioavailability. This innovative approach in designing pH‐responsive vesicular nanoaggregates using two biocompatible SAILs signifies a breakthrough in biomedical research, holding promise for advancements in drug delivery and therapeutic applications.

Targeting of nanoparticles to the cerebral vasculature after traumatic brain injury.

Traumatic brain injury has faced numerous challenges in drug development, primarily due to the difficulty of effectively delivering drugs to the brain. However, there is a potential solution in targeted drug delivery methods involving antibody-drug conjugates or nanocarriers conjugated with targeting antibodies. Following a TBI, the blood-brain barrier (BBB) becomes permeable, which can last for years and allow the leakage of harmful plasma proteins. Consequently, an appealing approach for TBI treatment involves using drug delivery systems that utilize targeting antibodies and nanocarriers to help restore BBB integrity. In our investigation of this strategy, we examined the efficacy of free antibodies and nanocarriers targeting a specific endothelial surface marker called vascular cell adhesion molecule-1 (VCAM-1), which is known to be upregulated during inflammation. In a mouse model of TBI utilizing central fluid percussion injury, free VCAM-1 antibody did not demonstrate superior targeting when comparing sham vs. TBI brain. However, the administration of VCAM-1-targeted nanocarriers (liposomes) exhibited a 10-fold higher targeting specificity in TBI brain than in sham control. Flow cytometry and confocal microscopy analysis confirmed that VCAM-1 liposomes were primarily taken up by brain endothelial cells post-TBI. Consequently, VCAM-1 liposomes represent a promising platform for the targeted delivery of therapeutics to the brain following traumatic brain injury.

Drug loading strategy of modular self‐assembly mode: Curcumin pyrimidine derivatives mediated by pH‐sensitive materials

AbstractChemotherapy drugs often cause various adverse reactions and affect normal tissues, so it is of great significance to design effective targeted anti‐tumor drug delivery methods. We constructed a series of self‐assembled supramolecular modular structures and explored whether they could become an effective targeted antitumor fluorescent agent. UV and fluorescence spectra show that it has fluorescence. The drug release curve was determined by dialysis method and the results showed that the release rate of PCB series composites was the highest under pH = 5. The curcumin pyrimidine derivative was embedded in the structure, and the formation of the complex was confirmed by infrared spectroscopy. The results for the cell imaging indicated that with the decrease of environmental pH value, the ability of PCB‐1 and PCB‐2 to penetrate the biofilm barrier into cells increased, suggesting that they have targeting action. The results of the cell viability test showed that PCB‐1 and PCB‐2 had a good inhibitory effect on MGC and HeLa cells. TEM showed that PCB‐1 was a regular hexahedron structure and PCB‐2 was a rod structure. In addition, the encapsulation efficiency of PCB‐1 and PCB‐2 was tested to be 86.50% and 88.57%, respectively, with drug loading rates of 27.62% and 28.38%, and Zeta potential values of +35 and +32. In conclusion, PCB‐1 and PCB‐2 are good potential anti‐tumor fluorescent agents.

Current Trends in Osmotic Pump Drug Delivery Systems

Traditional oral drug delivery methods, which typically release medication immediately, often lead to fluctuations in plasma drug concentration, potentially causing suboptimal therapeutic outcomes and side effects. Osmotic pump drug delivery systems address these issues by providing a controlled release mechanism that ensures a steady and predictable release of the drug over an extended period. This controlled release enhances patient compliance by reducing the frequency of dosing and maintaining uniform blood concentration levels, thereby improving therapeutic efficacy. Unlike conventional drug delivery methods, osmotic pumps are less influenced by physiological variables within the gastrointestinal tract, making them a reliable and consistent option for controlled drug delivery. These systems operate on the principles of osmosis, utilizing a semipermeable membrane to regulate the influx of water into the drug-containing core, which then generates osmotic pressure to drive the drug out through a delivery orifice. This review provides an in-depth discussion of the principles behind osmotic drug delivery systems, the various types available, their benefits, and the challenges they present. It also highlights the significance of these systems in modern pharmaceutical applications, demonstrating how they represent a significant advancement over traditional methods by optimizing drug release profiles, improving patient adherence, and ultimately enhancing therapeutic outcomes

Trojan Microparticles : A Composite Nanoparticle Delivery System

Abstract: In recent years, microparticulate systems have drawn growing attention as a viable strategy for delivering cells, proteins, and medications to target areas. The Nanoparticles-in-Microparticles System (NiMS) is a drug delivery method that combines nano- and microparticles to deliver medications or genes to particular bodily regions with precision. A promising method for achieving dual or multiple functions inside a formulation is the development of nanoparticle-in-microparticle systems (NiMS). NiMS comprises a microparticle (M.P.) matrix and one or more nanoparticles (N.P.s). The N.P.s can be designed to provide specific functionality, such as targeted drug delivery or imaging, while the M.P. matrix can be tailored to provide sustained release or protect the N.P.s from degradation. NiMS offer several advantages over traditional formulations, including the ability to control release profiles and achieve site-specific delivery. By combining different types of N.P.s and M.P.s, it is possible to create formulations that release drugs at different rates or with different kinetics, allowing for tailored treatment regimens. Additionally, by lowering off-target effects and boosting efficacy, the site-specific targeting offered by NiMS can enhance the therapeutic index of medications. Microparticles are small, micron-sized particles that can be loaded with therapeutic agents and designed to deliver them to specific tissues in the body. The pharmaceutical sector is developing microparticulate delivery systems for oral, pulmonary, and cutaneous administration. For instance, a promising strategy for treating respiratory conditions, including asthma and chronic obstructive pulmonary disease, is the development of inhalable microparticles (COPD). Moreover, the use of microparticles for topical drug delivery is being studied, where they can be formulated into creams, gels, or patches for treating skin disorders. The composition of microparticles is crucial for successful tissue regeneration because the particles must be biocompatible and able to interact with the cells in the targeted tissue. In addition, the size and shape of the particles can affect their behavior and how they interact with cells. Chemical and biological sensors and devices, optical detectors, electronic components, and nanoscale production depend on nanostructures because they offer unique properties, such as increased surface area and enhanced reactivity, which can be exploited to create more efficient and effective devices.

Stimuli-responsive Biomaterials for Tissue Engineering Applications.

The use of ''smart materials,'' or ''stimulus responsive'' materials, has proven useful in a variety of fields, including tissue engineering and medication delivery. Many factors, including temperature, pH, redox state, light, and magnetic fields, are being studied for their potential to affect a material's properties, interactions, structure, and/or dimensions. New tissue engineering and drug delivery methods are made possible by the ability of living systems to respond to both external stimuli and their own internal signals) for example, materials composed of stimuliresponsive polymers that self assemble or undergo phase transitions or morphology transformation. The researcher examines the potential of smart materials as controlled drug release vehicles in tissue engineering, aiming to enable the localized regeneration of injured tissue by delivering precisely dosed drugs at precisely timed intervals.

Formulation Consideration of Medicated Chewing Gum: A Review.

In recent times, technological and scientific advances have been made in studying and developing orally delivered medication. Such studies demonstrate the importance of the oral route among patients. The accuracy of drug delivery is very important to achieve a successful therapeutic effect in the case of various pharmaceutical products. A novel drug delivery system adds new benefits or advantages to a drug. This review covers all the aspects of medicated chewing gum (MCG) as a new drug delivery method, including the benefits and drawbacks, manufacturing methods, type of MCG, composition of chewing gum, evaluation parameters, factors that affected the release of API, its pharmaceutical significance, various marketed chewing gum and chewing gum packaging. Chewing gum as a drug delivery system has the potential to cure or prevent various indications, such as analgesic, CNS stimulation, smoking cessation, motion sickness, and treatment and prevention of dental caries or gingivitis. Pharmaceutical distribution to the oral mucosa can be made more convenient and enticing with the help of MCG. Compared to conventional techniques, this delivery system has a longer-lasting effect, which makes it a viable option for treating digestive problems, headaches, migraines, coughing, anxiety, and allergies.

PILOT STUDY OF INTRACOELOMIC TERBINAFINE IMPLANTS IN GREATER SIRENS (SIREN LACERTINA).

Chytridiomycosis caused by Batrachochytrium dendrobatidis (Bd) has been documented in greater sirens (Siren lacertina) in the wild and in the pet trade. This study evaluated the use of terbinafine-impregnated implants for chytridiomycosis prophylaxis in greater sirens exposed to Bd. Implants were placed intracoelomically in both control (blank implant, n = 4) and treatment (24.5 mg of terbinafine implant, n = 4) groups. Sirens were exposed to Bd zoospores via 24-h immersion bath at 1 and 2 mon postimplant placement. Blood was collected monthly for plasma terbinafine levels, and skin swabs were collected weekly for Bd quantitative PCR. Animals with terbinafine implants had detectable concentrations of plasma terbinafine ranging from 17 to 102 ng/ml. Only one terbinafine-implanted animal had a peak concentration above the published minimum inhibitory concentration for terbinafine against Bd zoospores (63 ng/ml); however, it is unknown how plasma terbinafine concentrations relate to concentrations in the skin. There was no difference between the two treatment groups in clinical signs or Bd clearance rate, and no adverse effects from implants were observed. These findings indicate using intracoelomic drug implants for drug delivery in amphibians is safe; however, terbinafine efficacy in preventing Bd chytridiomycosis in sirens remains unclear. Further investigation of the use of intracoelomic implants and identification of effective drugs and doses in other amphibian species against Bd and other infectious diseases is warranted, as this may provide a practical method for long-term drug delivery in wildlife.